# Proclara Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/proclara-biosciences

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.proclarabio.com
- Total disclosed funding: $17M
- Latest round: Series B (Mar 8, 2012)
- Investors on record: 2

## About

Proclara Biosciences, Inc. is a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, utilizing advanced scientific research to address unmet medical needs.Founded in 2006 and headquartered in Cambridge, US, Proclara Biosciences, Inc. specializes in biopharmaceuticals aimed at neurodegenerative conditions. The company has engaged in 11 investment deals, with the most recent deal occurring on November 9, 2018, where it raised USD 9.92 mn in venture funding. Their founder has a history of launching several successful ventures in the biotech sector.Proclara Biosciences, Inc. offers a range of biotechnology products focused on therapeutic interventions for neurodegenerative diseases. Their innovative solutions are designed to address the underlying mechanisms of these conditions, providing targeted treatments that aim to improve patient outcomes. The company serves a global market that includes North America, Europe, and parts of Asia, catering to both healthcare providers and research institutions.The revenue model for Proclara Biosciences, Inc. is based on the sale of specialized biotech therapeutics to healthcare organizations and research facilities. Their products are available through direct sales and strategic partnerships, ensuring accessibility to healthcare professionals and researchers. This approach fosters ongoing relationships with clients while facilitating continuous support and product enhancements.Proclara Biosciences, Inc. is currently focused on expanding its portfolio of therapeutic products for neurodegenerative diseases, with several new therapies slated for launch in the coming years. The company aims to penetrate additional markets across Europe and Asia by 2025, leveraging its most recent funding of USD 9.92 mn raised in November 2018 to support these initiatives. This investment will be utilized for research and development efforts, enhancing their product offerings and market reach.

## Funding rounds

- Series B, Mar 8, 2012, $9M — Shire, Merieux Equity Partners
- Series B, Mar 1, 2011, $8.4M — Shire, Merieux Equity Partners

## Investors

- Shire — Series B
- Merieux Equity Partners (https://capitalatlas.ai/funds/merieux-equity-partners) — Series B